Managing the risk of toxicity in the treatment of elderly patients with soft tissue sarcomas

References

• Soft tissue and bone tumours. WHO Classification of Tumours Editorial Board. Lyon (France): International Agency for Research on Cancer. 5th ed; 2020.
   Google Scholar
• Kallen M, Hornick J. The 2020 WHO classification: what’s new in soft tissue tumor pathology?. Am J Surg Pathol. 2020;Publish Ah(00):1–23.
   Google Scholar
• Younger E, Litière S, Le Cesne A, et al. Outcomes of elderly patients with advanced soft tissue sarcoma treated with first‐line chemotherapy: a pooled analysis of 12 EORTC soft tissue and bone sarcoma group trials. Oncologist. 2018;23(10):1250–1259.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/
   Google Scholar
• Basse C, Italiano A, Penel N, et al. Sarcomas in patients over 90: natural history and treatment—A nationwide study over 6 years. Int J Cancer. 2019;145(8):2135–2143. .
   PubMed Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: asco guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–2347.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–2603.
   PubMed Web of Science ®Google Scholar
• Burningham Z, Hashibe M, Spector L, et al. The Epidemiology of Sarcoma. Clin Sarcoma Res. 2012;2(1):14.
   PubMedGoogle Scholar
• Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49(3):684–695.
   PubMed Web of Science ®Google Scholar
• Ogura K, Higashi T, Kawai A, et al. Statistics of soft-tissue sarcoma in Japan: report from the bone and soft tissue tumor registry in Japan. J Orthop Sci. 2017;22(4):755–764.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zheng R, Zhang S, et al. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019;16(3):565–574.
   PubMed Web of Science ®Google Scholar
• Froehner M, Wirth PM. Etiologic factors in soft tissue sarcomas. Onkologie. 2001;24(2):139–142.
   PubMedGoogle Scholar
• Farid M, Ngeow J. Sarcomas associated with genetic cancer predisposition syndromes: a review. Oncologist. 2016;21(8):1002–1013.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: a population- based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer. 2011;57(6):943–949.
   PubMed Web of Science ®Google Scholar
• Hoven-Gondrie ML, Bastiaannet E, Ho VKY, et al. Worse survival in elderly patients with extremity soft-tissue sarcoma. Ann Surg Oncol. 2016;23(8):2577–2585.
   PubMed Web of Science ®Google Scholar
• Garbay D, Maki RG, Blay JY, et al. Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. Ann Oncol. 2013;24(7):1924–1930. .
   PubMed Web of Science ®Google Scholar
• Lahat G, Dhuka AR, Lahat S, Lazar AJ, Lewis VO, Lin PP, Feig B, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Lev D. Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. Ann Surg Oncol. 2009 Sep;16(9):2579–86
   PubMed Web of Science ®Google Scholar
• Gingrich AA, Bateni SB, Monjazeb AM, et al. Extremity soft tissue sarcoma in the elderly: are we overtreating or undertreating this potentially vulnerable patient population?. J Surg Oncol. 2019;119(8):1087–1098.
   PubMed Web of Science ®Google Scholar
• Smith HG, Thomas JM, Smith MJF, et al. ScienceDirect multivisceral resection of retroperitoneal sarcomas in the elderly. Eur J Cancer. 2016;69:119–126.
   PubMed Web of Science ®Google Scholar
• Al-Refaie WB, Habermann EB, Dudeja V, et al. Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI cancer trials. Ann Surg Oncol. 2010;17(8):1732–1738.
   PubMedGoogle Scholar
• Sourrouille I, Macovei R, Faron M, Le Péchoux C, Mir O, Adam J, Dumont S, Terrier P, Le Cesne A, Honoré C. Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, Single-Center Study. Ann Surg Oncol. 2018 Aug;25(8):2201–2208
   Google Scholar
• Okamoto M, Kito M, Yoshimura Y, et al. The status quo of treatment and clinical outcomes for patients over 80 years of age with high-grade soft tissue sarcoma: report from the soft tissue tumor registry in Japan. Jpn J Clin Oncol. 2018;48(7):900–905.
   PubMedGoogle Scholar
• Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, et al; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29\(Suppl 4):iv51-iv67
   Google Scholar
• Yuen NK, Li CS, Monjazeb AM, et al. Older age impacts radiotherapy-related outcomes in soft tissue sarcoma. J Surg Res. 2015;199(2):494–504.
   PubMed Web of Science ®Google Scholar
• Horiot JC. Radiation therapy and the geriatric oncology patient. J Clin Oncol. 2007;25(2):1930–1935.
   PubMedGoogle Scholar
• Parikh RC, Lorenzo M, Hess LM, et al. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. Clin Sarcoma Res. 2018;8(1):1–16.
   PubMedGoogle Scholar
• Mir O, Domont J, Cioffi A, Bonvalot S, Boulet B, Le Pechoux C, Terrier P, Spielmann M, Le Cesne A. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer. 2011 Mar;47(4):515–9
   Google Scholar
• Eugenie Y, Karla B, Yao L, et al. Journal of geriatric oncology subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. J Geriatr Oncol. 2019;(1):4–10. DOI:https://doi.org/10.1016/j.jgo.2019.05.008. Published online.
   Google Scholar
• Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1089–1103
   PubMed Web of Science ®Google Scholar
• Grünwald V, Karch A, Schuler M, et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. J clin oncol. 2020;38(30):3555–3564.
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Kopp H, Gruenwald V, et al. ScienceDirect randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. Eur J Cancer. 2020;124(August2019):152–160.
   PubMedGoogle Scholar
• JB., Lopez-Pousa A, Bui Nguyen B, Garcia Del Muro X, et al. A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: a GEIS trial. J Clin Oncol. 2011;29(15_suppl):10072.
   Web of Science ®Google Scholar
• Grosso F, D'Ambrosio L, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, et al. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group. Cancer. 2020 Nov 1;126(21):4726–4734
   PubMed Web of Science ®Google Scholar
• Cesne AL, Judson I, Maki R, et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age : a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013;109(7):1717–1724.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786–793.
   PubMed Web of Science ®Google Scholar
• Jones RL, Demetri GD, Schuetze SM, et al. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018;29(9):1995–2002.
   PubMed Web of Science ®Google Scholar
• Kasper B, Reichardt P, Schuler M, et al. Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): the E-TRAB study of the German interdisciplinary sarcoma group (GISG-13). Ann Oncol. 2017;28(5_suppl):v538
   Google Scholar
• Hamaker ME, Te Molder M, Thielen N, et al. The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients – a systematic review. J Geriatr Oncol. 2018;9(15_suppl):430–440.
   PubMedGoogle Scholar
• Versteeg KS, Konings IR, Lagaay AM, et al. Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. Ann Oncol. 2014;25(10):1914–1918.
   PubMed Web of Science ®Google Scholar
• Sourdet S, Brechemier D, Steinmeyer Z, Gerard S, Balardy L. Impact of the comprehensive geriatric assessment on treatment decision in geriatric oncology. BMC Cancer. 2020 May 6;20(1):384
   Google Scholar
• Jolly TA, Deal AM, Nyrop KA, et al. Geriatric assessment‐identified deficits in older cancer patients with normal performance status. Oncologist. 2015;20(4):379–385.
   PubMed Web of Science ®Google Scholar
• Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, Feng T, Smith D, Sun CL, De Glas N, Cohen HJ, Katheria V, Doan C, Zavala L, Levi A, Akiba C, Tew WP. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. J Clin Oncol. 2016 Jul 10;34(20):2366–71
   Google Scholar
• Yousaf N, Harris S, Martin-Liberal J, et al. First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. Clin Sarcoma Res. 2015;5(1):1–6.
   Google Scholar
• VanderWalde NA, Deal AM, Comitz E, et al. Geriatric assessment as a predictor of tolerance, quality of life, and outcomes in older patients with head and neck cancers and lung cancers receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(4):850–857.
   PubMed Web of Science ®Google Scholar
• Kenis C, Milisen K, Flamaing J, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014;32(1):19–26.
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012;118(13):3377–3386.
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–3465.
   PubMed Web of Science ®Google Scholar
• PACE participants, Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, West C, Corsini G, Maffezzini M, Hoekstra HJ, Mobarak D, Bozzetti F, Colledan M, Wildiers H, Stotter A, Capewell A, Marshall E. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008 Feb;65(2):156–63.
   Google Scholar
• Brunello A, Loaldi E, Balducci L, et al. Dose adjustment and supportive care before and during treatment. Cancer Treat Rev. 2009;35(6):493–498.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(October):iv96–iv110.
   PubMedGoogle Scholar
• Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015;26(July):v139–v151.
   PubMedGoogle Scholar
• Aapro M, Bernard-Marty C, Brain EGC, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22(2):257–267.
   PubMed Web of Science ®Google Scholar
• Erttmann R, Erb N, Steinhoff A, Landbeck G. Pharmacokinetics of doxorubicin in man: dose and schedule dependence. J Cancer Res Clin Oncol. 1988;114(5):509–13.
   PubMed Web of Science ®Google Scholar
• Toma S, Palumbo R, Sogno G, et al. Original article doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. Ann Oncol. 1992;3:S119–S123.
   PubMed Web of Science ®Google Scholar
• Jones RL. Utility of dexrazoxane for the reduction of anthracycline- induced cardiotoxicity. Published online. 2008;6(10):1311–1317.
   Google Scholar
• Spalato Ceruso M, Napolitano A, Silletta M, et al. Use of cardioprotective dexrazoxane is associated with increased myelotoxicity in anthracycline-treated soft-tissue sarcoma patients. Chemotherapy. 2019;64(2):105–109.
   PubMed Web of Science ®Google Scholar
• Li J, Chang HM, Banchs J, Araujo DM, Hassan SA, Wagar EA, Yeh ETH, Meng QH. Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin. Cardiooncology. 2020 Jan 2;6:1
   PubMedGoogle Scholar
• Biganzoli L, Lichtman S, Michel J, et al. Oral single-agent chemotherapy in older patients with solid tumours : a position paper from the international society of geriatric oncology (SIOG). Eur J Cancer. 2015;(17). DOI:https://doi.org/10.1016/j.ejca.2015.08.005 Published online.
   Google Scholar